Abstract
In the phase III EMERALD trial, the investigational oral selective estrogen receptor degrader elacestrant offered a modest but statistically significant improvement in progression-free survival in patients with ER-positive/HER2-negative breast cancer previously treated with endocrine therapy and a CDK4/6 inhibitor.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
